SMN2 Splicing Modulators for SMA Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for spinal muscular atrophy (SMA) lack effective drugs that address the underlying cause of the disease, with existing therapies focusing on supportive care and limited success in clinical applications, particularly for severe forms like Type 1 SMA, which is fatal in infancy.
Innovation Solution
Development of compounds that modulate the inclusion of exon 7 in mRNA transcribed from the SMN2 gene, enhancing the production of functional Smn protein by correcting alternative splicing, thereby potentially treating SMA by increasing the levels of functional Smn protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are developed to modulate exon 7 inclusion in SMN2 mRNA, then the level of functional Smn protein is increased, but the complexity of the treatment approach increases
Solution Approach 1:
The patent applies parameter changes by modifying the splicing parameters of SMN2 mRNA through small molecule compounds. These compounds alter the splicing machinery's behavior to favor exon 7 inclusion, thereby changing the output parameter from truncated to full-length Smn protein without altering the underlying SMN2 gene sequence.
Solution Approach 2:
The patent uses small molecule compounds as intermediaries to mediate between the SMN2 gene and the splicing machinery. These compounds bind to specific splicing regulatory elements or proteins, acting as mediators that shift the splicing equilibrium toward exon 7 inclusion and functional protein production.
2Reliability
If alternative splicing of SMN2 is corrected to include exon 7, then functional Smn protein levels increase, but the difficulty of detecting and measuring splicing efficiency increases
Solution Approach 1:
The patent employs reporter gene systems where splicing efficiency is coupled with detectable color changes or fluorescent signals. By fusing the SMN2 exon 7 region to reporter genes, successful splicing events produce detectable colorimetric or fluorescent readouts, simplifying the measurement of splicing efficiency.
Solution Approach 2:
The patent uses minigene constructs as simplified copies of the SMN2 gene that retain the critical splicing regulatory elements. These minigenes are easier to manipulate and assay in cell-based screens, allowing high-throughput detection of splicing modulators without the complexity of the full genomic context.
3Reliability
If exon 7 inclusion is enhanced in SMN2 mRNA, then the therapeutic effect for SMA is improved, but the loss of time for drug development and validation increases
Solution Approach 1:
The patent performs preliminary validation of splicing modulation using cell-based assays with SMN2 minigene constructs before advancing to complex in vivo models. This staged approach allows early identification of promising compounds and splicing mechanisms, reducing the time required for later-stage validation and accelerating the overall drug development timeline.
Solution Approach 2:
The patent segments the drug development process into distinct phases: initial cell-based splicing assays, validation in SMA mouse models, and clinical translation. This segmentation allows parallel development of multiple compound candidates through different validation stages, reducing the overall time to market by avoiding sequential bottlenecks.
Data Source
AI summary
Provided herein are compounds of Formula (I):and forms thereof, wherein w1, w2, w3, w4, w5, w6 and w7 are as defined herein, including compositions thereof and uses therewith for treating spinal muscular atrophy.